Skip to main content
. 2023 May 5;27:175. doi: 10.1186/s13054-023-04446-1

Table 3.

Primary and secondary outcomes

Primary outcome, 28-day survival in the Low-NED (≤ 0.25 µg/kg/min) subgroup
Placebo (n = 48) AT II (n = 56) HR (95% CI) p-value
48% (33%–61%) 64% (50%–75%) 0.51 (0.27, 0.95) 0.03
Secondary outcome, 28-day survival in the High-NED (> 0.25 µg/kg/min) subgroup
Placebo (n = 110) AT II (n = 107) HR (95% CI) p-value
45% (36–54%) 49% (39–58%) 0.93 (0.64, 1.35) 0.71

Values are expressed as median (IQR)

AT II, angiotensin II; NED, norepinephrine-equivalent dose